ERBB2 and breast carcinoma: When drug sensitivity prediction results were assessed by actual treatment response (pCR/RCB) in HER2- breast cancer patients, we found that the prospective individual predictions using the centroid model showed comparable results to those obtained using the unsupervised clustering-based prediction.